Voyager Therapeutics (VYGR) Current Deferred Revenue (2014 - 2026)
Voyager Therapeutics (VYGR) posted Current Deferred Revenue of $395000.0 for Q1 2026, down 75.16% sequentially from $1.6 million in Q4 2025, and down 98.13% YoY from $21.1 million in Q1 2025.
Voyager Therapeutics (VYGR) Current Deferred Revenue (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Current Deferred Revenue for 13 years, with the latest figure at $395000.0 in Q1 2026.
- Quarterly Current Deferred Revenue fell 98.13% year-over-year to $395000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $395000.0 (down 98.13% YoY) and the FY2025 annual result came in at $1.6 million, down 93.48% from the prior year.
- Current Deferred Revenue fell to $395000.0 in Q1 2026 per VYGR's latest filing, from $1.6 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $87.0 million in Q2 2022 and troughed at $395000.0 in Q1 2026.
- A 5-year average of $34.6 million and a median of $24.4 million in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2026: Current Deferred Revenue soared 978.24% in 2022, then slumped 98.13% in 2026.
- Over 5 years, Current Deferred Revenue stood at $59.4 million in 2022, then retreated by 27.78% to $42.9 million in 2023, then tumbled by 43.11% to $24.4 million in 2024, then slumped by 93.48% to $1.6 million in 2025, then slumped by 75.16% to $395000.0 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $395000.0, $1.6 million, and $10.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 244,000.00 |
| Mar 31, 2026 | 395,000.00 |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | 10.58 Mn |
| Jun 30, 2025 | 20.52 Mn |
| Mar 31, 2025 | 21.10 Mn |
| Dec 31, 2024 | 24.39 Mn |
| Sep 30, 2024 | 22.63 Mn |
| Jun 30, 2024 | 20.52 Mn |
| Mar 31, 2024 | 51.44 Mn |
| Dec 31, 2023 | 42.88 Mn |
| Sep 30, 2023 | 44.26 Mn |
| Jun 30, 2023 | 31.67 Mn |
| Mar 31, 2023 | 5.68 Mn |
| Dec 31, 2022 | 59.38 Mn |
| Sep 30, 2022 | 56.63 Mn |
| Jun 30, 2022 | 87.00 Mn |
| Mar 31, 2022 | 86.99 Mn |
| Dec 31, 2021 | 33.89 Mn |
| Sep 30, 2021 | 39.18 Mn |